Literature DB >> 10976772

The endothelin family: an overview.

T Masaki1.   

Abstract

Endothelin (ET) is a potent vasoconstrictive peptide initially found in the conditioned medium of cultured endothelial cells (1). It comprises 21 amino acid residues including four cysteine residues. The four cysteine residues form two intramolecular disulfide bonds. No amino acid sequence similar to that of ET had been previously reported. Furthermore its pharmacological action was unique. When it was injected intravenously into rats, a sustained and long-lasting pressor response was observed, suggesting a role of ET in maintenance of blood pressure or generation of hypertension. For these reasons many investigators were interested in this peptide. However, numerous reports following publication of the first paper detailing study of ET revealed that the mechanism for maintenance of blood pressure was not so simple. Apart from this problem, many pharmacological studies revealed that ET was active not only in the cardiovascular system but also in noncardiovascular systems. Those results stimulated further the worldwide interest in ET.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10976772     DOI: 10.1097/00005344-200000002-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  Endothelin-a receptor antagonists and advanced prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2004

2.  Expression of endothelins and their receptors in glioblastoma cell lines.

Authors:  Mayra Paolillo; Annalisa Barbieri; Patrizia Zanassi; Sergio Schinelli
Journal:  J Neurooncol       Date:  2006-03-24       Impact factor: 4.130

3.  Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.

Authors:  Gregory A Clines; Khalid S Mohammad; Yongde Bao; Owen W Stephens; Larry J Suva; John D Shaughnessy; Jay W Fox; John M Chirgwin; Theresa A Guise
Journal:  Mol Endocrinol       Date:  2006-10-26

4.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

5.  Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Emily Brantley; Seok Joong Yun; Junqin He; Marva Maya; Fahao Zhang; Qiuyu Wu; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

6.  Deficiency in Six2 during prenatal development is associated with reduced nephron number, chronic renal failure, and hypertension in Br/+ adult mice.

Authors:  Ben Fogelgren; Shiming Yang; Ian C Sharp; Odaro J Huckstep; Wenbin Ma; S J Somponpun; Edward C Carlson; Catherine F T Uyehara; Scott Lozanoff
Journal:  Am J Physiol Renal Physiol       Date:  2009-02-04

7.  Evolutionary Genetics of Hypoxia Tolerance in Cetaceans during Diving.

Authors:  Ran Tian; Zhengfei Wang; Xu Niu; Kaiya Zhou; Shixia Xu; Guang Yang
Journal:  Genome Biol Evol       Date:  2016-02-24       Impact factor: 3.416

8.  Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer.

Authors:  Frank Wiesmann; Jürgen Veeck; Oliver Galm; Arndt Hartmann; Manel Esteller; Ruth Knüchel; Edgar Dahl
Journal:  Breast Cancer Res       Date:  2009-06-15       Impact factor: 6.466

9.  Endothelin receptors as novel targets in tumor therapy.

Authors:  Anna Bagnato; Pier Giorgio Natali
Journal:  J Transl Med       Date:  2004-05-27       Impact factor: 5.531

10.  Cardioinotropic Effects in Subchronic Intoxication of Rats with Lead and/or Cadmium Oxide Nanoparticles.

Authors:  Svetlana V Klinova; Boris A Katsnelson; Ilzira A Minigalieva; Oksana P Gerzen; Alexander A Balakin; Ruslan V Lisin; Ksenia A Butova; Salavat R Nabiev; Oleg N Lookin; Leonid B Katsnelson; Larisa I Privalova; Daniil A Kuznetsov; Vladimir Ya Shur; Ekaterina V Shishkina; Oleg H Makeev; Irene E Valamina; Vladimir G Panov; Marina P Sutunkova; Larisa V Nikitina; Yuri L Protsenko
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.